Aktuelle Therapie der Hypertonie bei Diabetes

Zusammenfassung

Patienten mit Diabetes mellitus weisen ein deutlich erhöhtes kardiovaskuläres Risikoprofil auf, welches unter anderem durch ein gehäuftes Auftreten weiterer Risikofaktoren bedingt wird. Hierzu zählt die arterielle Hypertonie, die bei 70–90 % aller Patienten mit Diabetes mellitus auftritt und zu einer circa vierfachen Erhöhung des kardiovaskulären Risikos beiträgt. Zudem fördert die arterielle Hypertonie das Auftreten mikrovaskulärer Komplikationen bei diesen Patienten. Die vorliegende Arbeit gibt einen Überblick über pathophysiologische Hintergründe der arteriellen Hypertonie im Rahmen des Diabetes mellitus, der Wirkung auf mikro- und makrovaskuläre Komplikationen und die sich hieraus ergebenden therapeutischen Optionen.

Schlüsselwörter

Diabetes mellitus Typ2 - Hypertonie - Metabolisches Syndrom

Keywords

Type 2 diabetes - Hypertension - metabolic syndrome

• Literatur

• 1 Hypertension in Diabetes Study (HDS). II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-325
• 2 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713
• 3 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997
• 4 Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med 2008; 8: 533-543
• 5 Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH). Lancet 2010; 375: 1173-1181
• 6 Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581
• 7 Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372
• 8 Cushman WC, Evans GW, Byington P et al. ACCORD, Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585
• 9 Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652
• 10 Haller H, Ito S, Izzo JLJ et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
• 11 Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365
• 12 Jamerson K, Weber MA, Bakris GL et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428
• 13 Lindholm LH, Hansson L, Ekbom T et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-1675
• 14 Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 1004-1010
• 15 Mann JF, Schmieder RE, McQueen M et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008; 372: 547-553
• 16 Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53: 468-470
• 17 Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 2006; 144: 884-893
• 18 Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?. J Am Coll Cardiol 2009; 54: 1827-1834
• 19 Niskanen L, Hedner T, Hansson L et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091-2096
• 20 Parving HH, Brenner BM, McMurray JJ et al. on behalf of the ALTITUDE investigators. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13: 387-393
• 21 Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446
• 22 Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet 2007; 370: 829-840
• 23 Pyörälä M, Miettinen H, Halonen P et al. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000; 20: 538-544
• 24 Sarzani R, Salvi F, Dessì-Fulgheri P et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens 2008; 26: 831-843
• 25 Sharma AM, Engeli ST. The role of renin-angiotensin system blockade in the managment of hypertension asscociated with the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1: 29-35
• 26 Stojiljkovic L, Behnia R. Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007; 13: 1335-1345
• 27 Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603
• 28 Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol 2007; 27: 529-537
• 29 Zanchetti A, Hansson L, Clement D et al. HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?. J Hypertens 2003; 21: 797-804
• 30 Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-2168
• 31 Heß K, Marx N. Hypertonie und Diabetes. Aktuelle Aspekte zur Pathophysiologie und Therapie. Med Welt 2009; 60: 371-375